|
|
|
|
| LEADER |
01682nam a2200229 u 4500 |
| 001 |
EB002001605 |
| 003 |
EBX01000000000000001164506 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Drugs for pulmonary arterial hypertension
|h Elektronische Ressource
|b project protocol
|c Canadian Agency for Drugs and Technologies in Health
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c February 2014, 2014
|
| 300 |
|
|
|a 1 PDF file (ii, 10 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH therapeutic review report
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK355815
|3 Volltext
|
| 082 |
0 |
|
|a 800
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a CADTH will undertake a systematic review to compare the efficacy and safety of new and existing drug therapies for pulmonary arterial hypertension (PAH), and will examine their cost-effectiveness. The review will include drug therapies that are available in Canada (epoprostenol, treprostinil, bosentan, ambrisentan, macitentan, sildenafil, tadalafil) and one for which the clinical development program is advanced but is not yet approved for the treatment of PAH in Canada (riociguat). The clinical and cost-effectiveness evidence will be reviewed by the Canadian Drug Expert Committee (CDEC) for the purpose of making recommendations. Recommendations and advice delivered by CDEC are provided to CADTH participating jurisdictional drug programs to inform their policy decisions
|